Alliance Entertainment (NasdaqCM:AENT) Q2 2026 Earnings call February 12, 2026 04:30 PM ET Speaker3Greetings, and welcome to Alliance Entertainment's second quarter fiscal year 2026 financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I will now pass the call over to Paul Kuntz, a member of Alliance Entertainment's IR team at RedChip. Paul? Pardon me on ...

Financial Data and Key Metrics Changes - For Q4 2025, the company reported worldwide revenue of $1.26 billion, a 13% increase from $1.11 billion in Q4 2024, with organic growth at 12% [15][16] - U.S. revenue reached $892 million in Q4 2025, up 11% from $803 million in Q4 2024 [15] - International revenue grew 18% to $368 million in Q4 2025, with organic growth at 15% [16] - Gross profit for Q4 was $799.8 million, representing 63.5% of revenue, an increase from 59.4% in Q4 2024 [17] - Operating income was $331.5 million, or 26.3% of revenue, compared to $209.5 million, or 18.8% of revenue, in Q4 2024 [18] - Net income for Q4 was $265.1 million, equating to $0.68 per share [18] - The company closed the quarter with approximately $2 billion in cash and cash equivalents, indicating strong financial flexibility [18] Business Line Data and Key Metrics Changes - The rollout of the Dexcom G7 15-day system has received positive feedback, enhancing customer experience and potentially increasing market share [6][12] - The company is focusing on improving customer experience through new digital support systems and AI integration [7][8] - The early access launch of Dexcom Smart Basal aims to improve outcomes for Type 2 diabetes management [8] Market Data and Key Metrics Changes - The international business showed strength, particularly in Germany, the United Kingdom, and France, with France being one of the fastest-growing markets due to Type 2 access expansion [16] - The company anticipates that international market opportunities could surpass those in the U.S. over time [11] Company Strategy and Development Direction - The company aims to be the premier glucose sensing solution, focusing on sensor accuracy, reliability, and connectivity [6] - Strategic priorities include enhancing customer experience, expanding international market share, and driving growth through product innovation [10][11] - The company plans to introduce new products in 2026, including Stelo and a new CGM system for international markets [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in metabolic health management and the impact of upcoming Medicare coverage for Type 2 non-insulin users [24][26] - The company expects total revenue for 2026 to be in the range of $5.16 billion to $5.25 billion, reflecting growth of 11%-13% [19][20] - Management highlighted the importance of maintaining gross margin improvements and operational efficiencies while investing in new facilities [20][47] Other Important Information - The company has surpassed $1 billion in free cash flow for the first time in 2025 [19] - An Investor Day is planned for May 2026 to provide further details on the company's outlook [13] Q&A Session Summary Question: Discussion on the company's glucose sensing journey and market potential - Management believes the company is in the early stages of addressing metabolic health issues, with significant growth opportunities in Type 2 coverage expected in the next 12-24 months [24][26] Question: Inquiry about CMS coverage for Type 2 non-insulin users - Management is optimistic about upcoming CMS coverage decisions and is preparing for potential impacts on market access [30][33] Question: Impact of the 15-day product rollout on margins and new markets - The 15-day product is expected to contribute to margins over time, with significant opportunities for international expansion [36][39] Question: Discussion on operating expenses and investments - Increased operating expenses are primarily due to investments in the new Ireland manufacturing facility, which will enhance future production capabilities [46][47] Question: Utilization rates among different user segments - Utilization rates remain stable across various user segments, with high engagement expected to drive further growth [51][52] Question: Revenue outlook and new patient dynamics for 2026 - Revenue growth will depend on patient retention, utilization, and pricing strategies, with a focus on maintaining a stable user base [56][60] Question: Stability of the U.S. sensor uptake trends - Management noted improvements in sensor deployment and stable user retention, contributing to positive sell-through trends [64][66] Question: Pricing dynamics related to Medicare coverage - Pricing strategies will be influenced by competitive bidding processes, with expectations for stable pricing amidst increased volume [72][74] Question: International market growth strategies - The company plans to deepen its presence in existing markets and expand into new regions, with a focus on generating evidence to support market access [80][82]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $16 million, a 4% increase year-over-year, while full-year revenue reached $56.7 million, reflecting a 10% growth [3][17] - Gross profit for Q4 was $13.8 million, an 8% increase, with gross margin rising to 86% from 83% a year ago [19] - Net loss for Q4 was $11.9 million, or $0.46 per share, compared to a net loss of $10.7 million, or $0.43 per share in Q4 2024 [21] Business Line Data and Key Metrics Changes - U.S. revenue was $14.9 million in Q4 2025, a 4% increase, with revenue units totaling 478, up from 460 in the prior year [17] - European revenue increased to $1.1 million, a 10% rise, with revenue units growing to 49 from 41 [18] Market Data and Key Metrics Changes - The addressable market for Barostim therapy is estimated at $10.5 billion, with only 1% penetration, indicating significant growth potential [5] - The initiation of the BENEFIT-HF trial could expand the addressable market to approximately $30 billion if successful [12] Company Strategy and Development Direction - The company focused on three strategic priorities: building a world-class sales organization, driving deep adoption in targeted centers, and reducing barriers to adoption [6] - Transition to Category I CPT codes is expected to improve patient access and reimbursement predictability, effective January 1, 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sales team's ability to execute and drive growth, despite a natural ramp-up period for new sales representatives [6][15] - The company anticipates total revenue for 2026 to be between $63 million and $67 million, with a gross margin of 84% to 86% [23] Other Important Information - The company amended its debt facility to extend the maturity date to 2031 and increase access to additional capital [14][22] - A new Chief Human Resources Officer was appointed, indicating ongoing organizational development [16] Q&A Session Summary Question: On the BENEFIT-HF trial strategy and revenue generation - Management indicated that the trial will involve a mix of existing and new commercial sites, with expected revenue from approximately 1,600 to 1,700 devices sold during the trial [26][28] Question: Growth of active accounts in Q4 - Management noted that while there was a net addition of accounts, the focus remains on deepening existing relationships, with expectations of adding around three active territories quarterly in 2026 [30][31] Question: Impact of the Category I code on treatment barriers - Management reported positive early signs of improved prior authorization approvals and expects this trend to continue as the transition progresses [36][39] Question: Path to profitability and cash management - The company has sufficient cash reserves and access to additional capital, with a focus on driving sales productivity to achieve profitability [72][74]

Financial Data and Key Metrics Changes - Revenues for Q4 2025 were $4.9 million, a significant decrease from $31 million in Q4 2024, primarily due to lower unit sales [13] - Gross profit for Q4 2025 was $1.9 million, or 38.8% of revenues, down from $7.1 million, or 54.2% in Q4 2024, driven by lower sales and higher servicing costs [14] - For the full year 2025, revenues were $27.5 million, compared to $41.8 million in 2024, reflecting a decrease in unit sales [15] - The net loss for 2025 was $7.7 million, or a loss of $0.47 per share, compared to a net income of $6.6 million, or $0.41 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - The company shipped 14 units in Q4 2025, with 8 in the U.S. and 6 internationally, but did not include sales to its largest customer [24] - The Fair Deal Agreement program saw substantial year-over-year utilization increases, with treatments up more than eightfold and the number of patients treated increasing by over 250% in 2025 [7] Market Data and Key Metrics Changes - International sales were strong in Q4 2025, with shipments to China and a growing demand in Asia, particularly in Taiwan and South Korea [8][28] - The company expects international markets to remain a significant part of its growth strategy, with Brazil and the Middle East also showing potential [29] Company Strategy and Development Direction - The introduction of new CPT codes for SRT and IG-SRT technologies is expected to enhance physician reimbursement and support broader adoption of non-invasive treatments [4] - The company aims to achieve full-year profitability in 2026, supported by a diversified customer base and expanding international opportunities [9] - A disciplined approach to scaling the sales organization is being implemented, with plans to hire additional sales representatives to enhance market education and lead conversions [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with improved clarity and control over the business, emphasizing the positive impact of new reimbursement codes [20] - The company is focused on converting interest into system placements as the year progresses, with expectations for Q1 revenues to exceed Q4 levels [19] Other Important Information - The company ended 2025 with $22.1 million in cash and cash equivalents, with no outstanding debt, indicating a strong balance sheet [18] - Research and development expenses for 2025 increased to $7.8 million, reflecting higher costs related to billing and reimbursement efforts [17] Q&A Session Summary Question: Does the revenue growth guidance for Q1 assume no contribution from the largest customer? - Management confirmed that projections for 2026 exclude expectations from the largest customer, and any contribution from them would be considered upside [24] Question: What is the status of the TDI program and expected FDA approval? - Management indicated ongoing efforts with the FDA but could not provide a timeline for approval [26] Question: What is the demand outlook internationally for 2026? - Management highlighted strong demand in China and growth in Taiwan, with expectations for expansion in South Korea, Japan, and potential entry into Brazil and the Middle East [28][29] Question: How has the reaction to reimbursement affected system mix and financing options? - Management noted a shift towards outright purchases and leasing options due to guaranteed reimbursements, with a stronger focus on SRT products [38][40] Question: What is the outlook for service revenue? - Service revenue remains consistent at about 10% of total revenue, with no expected changes [48]

Expedia Group (NasdaqGS:EXPE) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Speaker9Hello, everyone. Thank you for joining us, and welcome to the Expedia Group Q4 2025 financial results webcast. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, press star one again. For opening remarks, I will now hand the call over to Rob Bevegni, VP of Investor Relations. Please g ...

Legacy Education (NYSEAM:LGCY) Q2 2026 Earnings call February 12, 2026 04:30 PM ET Speaker5Good day, and welcome to the Legacy Education Inc.'s second quarter fiscal year 2026 earnings conference call. Today's call is being recorded and broadcast live. It will also be archived on the Legacy Education website for future reference. To kick off the call, I will turn it over to Nicole Joseph, Senior Vice President of Legacy Education, Inc.Speaker4Thank you, and hello, everyone. Legacy Education has issued a new ...

Financial Data and Key Metrics Changes - Revenue for the second fiscal quarter of 2026 was $14.1 million, up from $13.2 million in the prior quarter, but down from $16.8 million in the same quarter last year [16] - Gross margin increased to 34.7% from 28.6% in the prior quarter and 32.5% in the prior year, reflecting improved product mix and cost-saving initiatives [16] - Operating expenses decreased to $4.1 million from $5.9 million in the prior quarter and $6.9 million in the same quarter of 2025, a 31% sequential decrease [17] - Net income for the second quarter was $0.6 million, or $0.03 per share, compared to a net loss of $2.6 million in the prior quarter [17] - Adjusted EBITDA for the second quarter was positive $1.5 million, compared to an adjusted EBITDA loss of $1.4 million in the prior quarter [18] Business Line Data and Key Metrics Changes - The company achieved net profitability for the first time in its history, attributed to expense optimization and sequential revenue growth [4][12] - The product development team made significant progress, particularly with the launch of the next-generation SkyLink telematics device [9] - The new GAT 315 battery was released in response to customer demand in the GSE segment, expanding the product line to four with multiple configurations [10] Market Data and Key Metrics Changes - The lithium-ion forklift battery segment is projected to grow at an 8.8% CAGR through 2035, indicating strong long-term market opportunities [15] - The company is experiencing a capital freeze from its most significant customer, which may impact revenue for a significant portion of calendar year 2026 [13] Company Strategy and Development Direction - The company focuses on five strategic initiatives: profitable growth, operational efficiencies, solution selling, building the right products, and integrating value-added software [5] - The integration of AI-driven tools in engineering design and operations aims to improve operational efficiencies and productivity [6] - The company is expanding its sales leadership and hiring experienced personnel to enhance customer engagement and drive growth [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate current market pressures and restore profitable growth despite the capital freeze from a key customer [14] - The management team is focused on reducing expenses and optimizing operations to maintain profitability [15] - There is cautious optimism regarding demand, with customers needing to purchase batteries to sustain their operations despite tariff impacts [24] Other Important Information - The company recorded a $0.5 million reversal of previously accrued employee bonus awards, which will not impact future quarters [17][45] - The SkyEMS software was upgraded to include intelligent alerting features, which are expected to improve fleet management and productivity [11] Q&A Session Summary Question: Is the capital freeze unique to one customer or indicative of broader industry trends? - Management confirmed that the capital freeze is specific to one customer [23] Question: How is the overall demand environment characterized? - Management noted that while tariff effects linger, customers still need to purchase batteries to run their businesses [24] Question: What is the rollout strategy for the SkyLink product? - The SkyLink telematics will be offered across the product line, with positive initial feedback from beta tests [25][26] Question: Will cost savings and warranty costs remain low to support gross margins? - Management indicated that they are taking steps to lower product costs and expect positive trends in warranty and repair costs [29][31] Question: What is the strategy for filling the revenue gap from the significant customer? - The company is actively hiring new sales personnel and focusing on material handling to replace lost revenue [36] Question: Will new SkyLink features be sold at a premium? - Management plans to offer a standard and a premium version of the software, with higher gross margins expected from premium sales [38][39] Question: Can you elaborate on the State of Health patent and its revenue potential? - The patent includes algorithms for battery health insights, which will be part of the premium software package, generating potential revenue [40][41]

Trupanion (NasdaqGM:TRUP) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Speaker5Good day, and welcome to the Trupanion fourth quarter 2025 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on a touch-tone phone. To withdraw your question, please press star ...

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $20.1 million, a 30% year-over-year increase and 16% sequential growth, exceeding guidance [20] - For the full year 2025, total revenue was $70.6 million, representing a 22% increase year-over-year [20] - Annual contract value plus royalties hit a record $83.6 million, up 28% year-over-year [21] - Remaining performance obligations (RPO) totaled $117 million, a 32% year-over-year increase, with approximately half expected to be recognized as revenue in 2026 [21] - Non-GAAP gross profit for Q4 was $18.5 million, with a gross margin of 92% [22] - Non-GAAP operating loss for Q4 was $2.2 million, while the full year loss was $12.5 million, an improvement over the previous year [25] Business Line Data and Key Metrics Changes - The company reported a significant increase in variable royalties, which were 50% higher year-over-year, with Q4 setting a new record [20] - The number of large royalty reporters tripled over the last two years, contributing to a balanced mix of customers across vertical markets [20] - FlexGen, an AI-driven smart NoC IP product, saw strong adoption with over 30 production device deployments [11] - Ncore, a cache coherent interconnect IP product, also experienced strength in licensing across various applications [12] Market Data and Key Metrics Changes - The company noted expanding demand for AI-driven semiconductor designs across various markets, including enterprise computing, automotive, and consumer electronics [6] - The number of chiplet projects incorporating Arteris technology has more than tripled over the past two years, indicating strong market growth [15] - The automotive segment remains the largest vertical market, with emerging strength in consumer and aerospace sectors [39] Company Strategy and Development Direction - The acquisition of Cycuity enhances the company's product portfolio by adding cybersecurity assurance products, addressing market concerns about increasing cyberattacks [8][9] - The company aims to leverage its technology to improve hardware security and vulnerability testing across all SoCs, expanding its customer base [10] - Arteris is focusing on supporting semiconductor applications in the AI era, with a strong position in various sectors including autonomous vehicles and industrial automation [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, expecting to report a non-GAAP operating profit as early as Q4 2026 [28] - The company anticipates continued strong demand for its products driven by the rise of AI and the need for efficient data movement in semiconductors [6] - Management highlighted the importance of addressing cybersecurity in semiconductor designs, which is becoming a critical issue in the industry [30] Other Important Information - The company ended the year with $59.5 million in cash and no financial debt, with positive free cash flow of $3 million for Q4 [26] - The guidance for Q1 2026 includes expected ACV plus royalties of $85 million-$89 million and revenue of $20.5 million-$21.5 million [27] Q&A Session Summary Question: Cross-sell opportunities and customer segments - Management indicated that hardware security assurance is a growing issue, and the acquisition opens significant opportunities to enhance system IP value across various semiconductor companies [30][31] Question: NXP announcement and customer interest - Management confirmed that NXP is now using four solutions, indicating increased interest in deploying a full suite of solutions, which could drive average selling prices above $1 million [36] Question: Strength in royalties and market segments - Management noted that the growth in royalties is attributed to both customer diversification and an increase in large royalty reporters across various segments, including automotive and consumer markets [38][39] Question: Impact of security on P&L - Management clarified that approximately $7 million of the projected revenue for 2026 is expected from the Cycuity acquisition, with a slight contribution to operating loss anticipated [47] Question: Equity raising efforts post-acquisition - Management stated that they are in the process of activating an ATM for equity raising, with expectations for small amounts to be raised in the first quarter [49]

AVITA Medical (NasdaqCM:RCEL) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Speaker5day, and thank you for standing by. Welcome to the AVITA Medical, Inc. fourth quarter and full year 2025 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press star one one on your telephone. You will then hear an automated message advising your hand is raise ...